Suyu Liu
Department of Biostatistics, Division of Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Associate Professor, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Regular Member of the Graduate Faculty, Department of Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX
Education & Training
Degree-Granting Education
| 2012 | University of Texas, Houston, TX, USA, PHD, Biostatistics |
| 2005 | University of Michigan, Ann Arbor, MI, USA, MS, Biostatistics |
| 2003 | Eastern Michigan University, Ypsilanti, MI, USA, MS, Computer Science |
| 1999 | Huazhong University of Science and Technology, Wuhan, CHN, BS, Biomedical Engineering |
Postgraduate Training
| 2012-2014 | Postdoctoral Fellow, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX |
Experience & Service
Institutional Committee Activities
Admission committee member, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, 2020 - Present
Honors & Awards
| 2008 | Outstanding Contribution, The University of Texas MD Anderson Cancer Center |
| 2007 | Outstanding Contribution, The University of Texas MD Anderson Cancer Center |
| 2003 | Outstanding Service as a Tutor, Eastern Michigan University |
| 2003 | Outstanding Graduate, Eastern Michigan University |
| 2002 | Excellence in Mathematics Awards, Eastern Michigan University |
| 1999 | Outstanding Undergraduate, Huazhong University of Science & Technology |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Liu S, Yuan Y, Castillo R, Guerrero T, Johnson VE. Evaluation of image registration spatial accuracy using a Bayesian hierarchical model. Biometrics 70(2):366-77, 2014. e-Pub 2014. PMID: 24575781.
- Jin IH, Liu S, Thall PF, Yuan Y. Using data augmentation to facilitate conduct of phase I/II clinical trials with delayed outcomes. J Am Stat Assoc 109(506):525-536, 2014. PMID: 25382884.
- Ahn J, Liu S, Wang W, Yuan Y. Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts. Biometrics 69(4):914-24, 2013. e-Pub 2013. PMID: 24328715.
- Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 19(24):6967-75, 2013. e-Pub 2013. PMID: 24166906.
- Liu S, Yin G, Yuan Y. Bayesian Data Augmentation Dose Finding With Continual Reassessment Method And Delayed Toxicity. Ann Appl Stat 7(4):1837-2457, 2013. PMID: 24707327.
- Liu S, Cai C, Ning J. Up-and-down designs for phase I clinical trials. Contemp Clin Trials 36(1):218-27, 2013. e-Pub 2013. PMID: 23856381.
- Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol 8(5):658-61, 2013. PMID: 23584298.
- Liu S, Ning J.. Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities. Bayesian Analysis 8:703-722, 2013. PMID: 27924182.
- Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol 7(11):1645-52, 2012. PMID: 23059780.
- Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 104(3):228-39, 2012. e-Pub 2012. PMID: 22247021.
- Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 6(12):2104-11, 2011. PMID: 21892101.
- Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, De la Cerda J, Eagle C, Viner JL, Palmer JL, Lerner SP. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) 4(10):1580-9, 2011. e-Pub 2011. PMID: 21881030.
- Momoh AO, Yu P, Skoracki RJ, Liu S, Feng L, Hanasono MM. A prospective cohort study of fibula free flap donor-site morbidity in 157 consecutive patients. Plast Reconstr Surg 128(3):714-20, 2011. PMID: 21572380.
- Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1(1):44-53, 2011. e-Pub 2011. PMID: 22586319.
- Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med 30(11):1218-29, 2011. e-Pub 2011. PMID: 21432894.
- Savar A, Esmaeli B, Ho H, Liu S, Prieto VG. Conjunctival melanoma: local-regional control rates, and impact of high-risk histopathologic features. J Cutan Pathol 38(1):18-24, 2011. e-Pub 2010. PMID: 20860727.
- Lee JJ, Xuemin Gu , Suyu Liu. Bayesian adaptive randomization designs for targeted agent development. Clin Trials 7(5):584-96, 2010. e-Pub 2010. PMID: 20571130.
- Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer 10(1):46-51, 2010. PMID: 20133258.
- Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15(17):5359-68, 2009. e-Pub 2009. PMID: 19706809.
- Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, Wolff RA, Tortorice ML, Tansey P, Gonzalez-Moreno S, Lambert DH, Mansfield PF. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 16(8):2181-7, 2009. e-Pub 2009. PMID: 19475451.
- Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer 115(5):1091-9, 2009. PMID: 19165805.
- William WN, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ES. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol 32(1):15-9, 2009. PMID: 19194117.
- Ross WA, Ghosh S, Dekovich AA, Liu S, Ayers GD, Cleary KR, Lee JH, Couriel D. Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol 103(4):982-9, 2008. e-Pub 2007. PMID: 18028511.
- Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials 5(3):181-93, 2008. PMID: 18559407.
- Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-72, 2007. PMID: 17620427.
- Goetz DH, Lee JH, Davila ML, Liu S, Fukami N, Ross W.. Performance of Covered vs. Uncovered Metal Stents in Malignant Strictures of the Common Duct. Gastrointestinal Endoscopy 65(5):AB222-AB222, 2007.
- Raffel DM, Koeppe RA, Little R, Wang CN, Liu S, Junck L, Heumann M, Gilman S. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 47(11):1769-77, 2006. PMID: 17079809.
- Consens FB, Chervin RD, Koeppe RA, Little R, Liu S, Junck L, Angell K, Heumann M, Gilman S. Validation of a polysomnographic score for REM sleep behavior disorder. Sleep 28(8):993-7, 2005. PMID: 16218083.
- Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, Frey KA, Albin RL. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 46(6):936-44, 2005. PMID: 15937303.
Abstracts
- Liu S, Yin G, Yuan Y. Bayesian Data Augmentation Dose Finding with Continual Ressessment Method and Delayed Toxicities. IBS, 2014.
- Tsao AS, Liu S, Lee JJ, Alden CM, Kim ES, Blumenschein GR, Herbst RS, Lippman SM, Wistuba II, Hong WK. Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy- Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. ASCO, 2011.
- Herbst RS, Blumenschein GB, Kim ES, Lee JJ, Tsao AS, Alden CM, Liu S, Stewart DJ, Wistuba II, Hong WK. Sorafenib Treatment Efficacy and KRAS Biomarker Status in the BATTLE Trial (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination). Journal of Clinical Oncology, 2010.
- Liu S, Lee JJ. Design, Implementation, and Results for a Bayesian Adaptive Randomized Trial for Targeted Therapy in Lung Cancer. JSM, 2010.
Grant & Contract Support
| Title: | Blood-based Markers for Screening and Early Detection of Colorectal Neoplasia |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | Pancreatic Cyst Fluid miRNOME for Biomarkers of Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND): A randomized phase II basket trial to assess local control for oligometastatic disease |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Prostate Cancer-Induced Bone Formation Regulates Immune Microenvironment in Prostate Cancer Bone Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Randomized Trial of Adjuvant Immunotherapy after XRT for Oligometastatic Renal Cell Carcinoma (TEXAN) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | DEAR1 as a Critical Regulator of Epithelial-Mesenchymal Plasticity to Stratify Triple Negative Breast Cancers for Precision Therapy using an Organoid Model |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
Patient Reviews
CV information above last modified August 27, 2024